Back to Results
First PageMeta Content
Anti-diabetic drugs / Amides / Sulfonylureas / Nitriles / Saxagliptin / Anti-diabetic medication / Metformin / Sitagliptin / Linagliptin / Chemistry / Organic chemistry / Dipeptidyl peptidase-4 inhibitors


Information for Health Care Professionals Transitioning Patients to a Different Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Background Ten classes of antihyperglycemic medications are currently approved for use in type 2 d
Add to Reading List

Document Date: 2014-10-06 15:16:38

Open Document

File Size: 363,32 KB

Share Result on Facebook

City

Ottawa / /

Company

PharmaCare Limited / Canadian Agency for Drugs / /

Country

Canada / /

Currency

USD / /

Event

FDA Phase / Product Issues / /

IndustryTerm

e-cps / saxagliptin-metformin products / sitagliptin products / /

MedicalCondition

ESRD / Diabetes / J Diabetes / diabetes mellitus / heart failure / pancreatitis / severe hypoglycemia / end-stage renal disease / /

MedicalTreatment

pharmacotherapy / /

Organization

Canadian Agency for Drugs and Technologies / Canadian Diabetes Association / Canadian Diabetes Association Clinical Practice Guidelines Expert Committee / Pharmaceutical Services Division / Special Authority / Canadian Pharmacists Association / Canadian Drug Expert Committee / /

Position

Governor / Health Care Professionals General / /

Product

pioglitazone / One tablet / Janumet / XR tablet / glyburide / Assuming / Dosage Forms 2.5 / Januvia / Recommended Dose One tablet / Kazano® / Trajenta® / glycemic control / /

PublishedMedium

the Common Drug Review / /

URL

www.health.gov.bc.ca/pharmacare/pdf/DDS-0054.pdf / www.e-cps.ca / www.health.gov.bc.ca/pharmacare/sa/saindex.html / /

SocialTag